These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23599815)

  • 21. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
    Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
    Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
    Ringel F; Kaeda J; Schwarz M; Oberender C; Grille P; Dörken B; Marque F; Manley PW; Radimerski T; le Coutre P
    Acta Haematol; 2014; 132(1):75-86. PubMed ID: 24504330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance.
    Martin-Cabrera P; Haferlach C; Kern W; Schnittger S; Haferlach T
    Br J Haematol; 2017 Jan; 176(1):135-139. PubMed ID: 26847954
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
    Nadarajan VS; Ang CH; Bee PC
    Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 28. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
    Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
    Kim YK; Shin MG; Kim HR; Yang DH; Cho SH; Lee JJ; Chung IJ; Ryang DW; Kim HJ
    Leuk Res; 2008 Jun; 32(6):993-5. PubMed ID: 18055011
    [No Abstract]   [Full Text] [Related]  

  • 30. Transformation of polycythemia vera to chronic myelogenous leukemia.
    Mirza I; Frantz C; Clarke G; Voth AJ; Turner R
    Arch Pathol Lab Med; 2007 Nov; 131(11):1719-24. PubMed ID: 17979493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
    Zhou A; Knoche EM; Engle EK; Fisher DA; Oh ST
    Blood Cancer J; 2015 Oct; 5(10):e351. PubMed ID: 26430722
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report.
    Tirrò E; Stella S; Massimino M; Zammit V; Pennisi MS; Vitale SR; Romano C; Di Gregorio S; Puma A; Di Raimondo F; Stagno F; Manzella L
    Acta Haematol; 2019; 141(4):261-267. PubMed ID: 30965317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM; Bagg A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders.
    Pastore C; Nomdedeu J; Volpe G; Guerrasio A; Cambrin GR; Parvis G; Pautasso M; Daglio C; Mazza U; Saglio G
    Genes Chromosomes Cancer; 1995 Oct; 14(2):106-11. PubMed ID: 8527391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
    Yan J; Ding YW; Wang PY; Wu YP; Zhang HC; Liu LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
    Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
    Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
    [No Abstract]   [Full Text] [Related]  

  • 38. Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.
    Toogeh G; Ferdowsi S; Naadali F; Alimoghaddam K; Ghavamzadeh A; Shirkoohi R; Ghaffari SH
    Med Oncol; 2011 Dec; 28(4):1555-8. PubMed ID: 20499211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
    Tefferi A; Skoda R; Vardiman JW
    Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.
    Wang X; Tripodi J; Kremyanskaya M; Blouin A; Roda P; Hoffman R; Najfeld V
    Blood; 2013 Feb; 121(7):1238-9. PubMed ID: 23411734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.